HK Stock Market Move | BAO PHARMA-B(02659) rises more than 9% and officially joins the Hong Kong Stock Exchange. Major catalytic events are expected to facilitate commercial transformation within the year.

BAO PHARMA-B (02659) rose by over 9%, reaching a 7.21% increase at the time of publication, closing at 111.5 Hong Kong dollars with a trading volume of 13.5474 million Hong Kong dollars. On the news front, BAO PHARMA-B announced that according to the regulations of the Shanghai Stock Exchange and Shenzhen Stock Exchange regarding the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, the company's shares (H shares) listed on The Stock Exchange of Hong Kong Limited will be included as eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs starting from March 9, 2026. This move signifies the company's formal entry into the view of mainland investors, and it is expected to bring dual opportunities through capital access and revaluation. It is understood that Baoji Pharmaceutical is expected to see significant catalytic effects on the commercialization front, with several core products expected to bring in substantial revenue this year. Xiniu Securities pointed out that KJ017 (recombinant human hyaluronidase) is expected to receive NDA approval in 2026. Currently, recombinant human hyaluronidase is not sold as a monotherapy in the Chinese market, but once it is launched, it may unleash substantial commercial potential, potentially accelerating the company's commercialization process. The company's self-developed long-acting recombinant human follicle-stimulating hormone (FSH-CTP) injection Shenowa (SJ02) has been approved for market launch and has reached an exclusive sales agreement for the Greater China region with Anhui Anke Biotechnology (300009.SZ), successfully realizing commercial landing.